StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
NPCE$18.35+0.00%
Fair $18.35+0.0%

NPCE

NeuroPace, Inc.

Healthcare / Medical DevicesNasdaqGM

$18.35

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $18.35Fund rank 21/100 · Data gapFallback financials|
SA 9/F
F-Score: 6/9
High DebtLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 16%

FCF escenarios

weak_data · normalized FCF $-18.3M · quality 35.0/100

Data gap 21/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 29/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

9/100

F

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 6Warnings: 2unknown: 6
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Debt-to-Equity ratio is 3.09, above the 2.0 threshold ROE is -1.1%, below the 5% threshold
Thesis & Journal · NPCELocal privado en este navegador · NeuroPace, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$623M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-112.8%

↓

Gross Margin

77.2%

↑

Debt/Equity

3.09

↑
No hay histórico de precio usable para pintar el gráfico TradingView.

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2020–2025 · 5 años de histórico normalizado

Revenue CAGR

+19.4%

FCF CAGR

—

FCF margin

-11.3%

FCF / Net income

0.53x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $100.0M · net income $-21.5M · FCF $-11.3M

2020-FY → 2025-FY

Gross margin

77.2%+3.6% pts

Operating margin

-16.3%+15.4% pts

Net margin

-21.5%+37.5% pts

FCF margin

-11.3%+41.3% pts
MetricTTM
2025
2024
2023
2022
2021
2020
Income Statement
Revenue$100.0M$100.0M$79.9M$65.4M$45.5M$45.2M$41.1M
Net Income$-21.5M$-21.5M$-27.1M$-33.0M$-47.1M$-36.1M$-24.3M
EPS-0.66-0.66-0.93-1.27-1.91-2.17-117.85
Gross Margin77.2%77.2%73.9%73.6%71.4%74.0%73.6%
Operating Margin-16.3%-16.3%-27.1%-41.5%-89.6%-52.5%-31.7%
Net Margin-21.5%-21.5%-34.0%-50.4%-103.4%-79.9%-59.0%
Balance Sheet
Debt/Equity3.093.097.432.761.520.68-0.34
Cash Flow
Free Cash Flow$-11.3M$-11.3M$-18.3M$-19.9M$-37.5M$-25.0M$-21.7M
Returns
ROE-112.8%-112.8%-338.7%-159.6%-135.4%-49.1%16.4%
Growth & Yield
Revenue Growth25.1%25.1%22.1%43.7%0.7%9.8%—
EPS Growth29.0%29.0%26.8%33.5%12.0%98.2%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total n/d
Return attribution requires positive start and end prices.

Unavailable: positive start/end prices are required.